key: cord-0772624-5p7nkkvt
authors: Amanat, Fatima; Strohmeier, Shirin; Meade, Philip S.; Dambrauskas, Nicholas; Mühlemann, Barbara; Smith, Derek J.; Vigdorovich, Vladimir; Sather, D. Noah; Coughlan, Lynda; Krammer, Florian
title: Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus
date: 2021-12-16
journal: PLoS Biol
DOI: 10.1371/journal.pbio.3001384
sha: c5170d6c3a1bef88ed1869b8d523710d7f3540cd
doc_id: 772624
cord_uid: 5p7nkkvt

Vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been highly efficient in protecting against Coronavirus Disease 2019 (COVID-19). However, the emergence of viral variants that are more transmissible and, in some cases, escape from neutralizing antibody responses has raised concerns. Here, we evaluated recombinant protein spike antigens derived from wild-type SARS-CoV-2 and from variants B.1.1.7, B.1.351, and P.1 for their immunogenicity and protective effect in vivo against challenge with wild-type SARS-CoV-2 in the mouse model. All proteins induced high neutralizing antibodies against the respective viruses but also induced high cross-neutralizing antibody responses. The decline in neutralizing titers between variants was moderate, with B.1.1.7-vaccinated animals having a maximum fold reduction of 4.8 against B.1.351 virus. P.1 induced the most cross-reactive antibody responses but was also the least immunogenic in terms of homologous neutralization titers. However, all antigens protected from challenge with wild-type SARS-CoV-2 in a mouse model.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in late 2019 in Wuhan, China. Since then, the virus has caused the Coronavirus Disease 2019 (COVID- 19) a1111111111 a1111111111 a1111111111 a1111111111 a1111111111

First, we vaccinated BALB/c mice twice with adjuvanted recombinant spike proteins of wildtype SARS-CoV-2 (Wuhan-1), B.1.1.7, B.1.351, and P.1. Three weeks postboost, the animals were bled and the neutralizing activity of their serum was assessed in a well-established microneutralization assay with authentic SARS-CoV-2 [22] . When tested against the respective virus from which the vaccine antigen was derived, all animals mounted strong neutralizing antibody responses (Fig 1A; geometric mean neutralization titers of 6,924, 6,673, 4,690, and 3,246 for wild type, B.1.1.7, B.1.351, and P.1, respectively), while negative controls showed no neutralizing activity (Fig 1B) . The negative control group received an irrelevant control protein, influenza virus hemagglutinin. However, there was a trend toward B.1.1.7-vaccinated animals showing higher neutralizing capacity against homologous virus as compared to the other spike variant antigens. P.1 seemed to induce the lowest neutralizing activity against homologous viruses. These differences were small and only significant for B.1.1.7 versus P.1.

As expected, when testing for cross-reactivity, the different spike proteins induced the highest neutralization titers against the homologous viruses. Sera from wild-type spike-vaccinated animals neutralized WA1 best, followed by B.1.1.7, P.1, and B.1.351 (Fig 1C; geometric mean neutralization titers of 6,924, 4,994, 2,071, and 2,291 for wild type, B.1.1.7, B.1.351, and P.1, respectively). Sera from B. . Importantly, we did not observe complete loss in neutralizing activity against any of the viruses. We used antigenic cartography [23] to visualize the antigenic relationships between the tested viruses and sera (Fig 2) . The B.1.351 virus is positioned furthest from the WA1 virus, and P.1 and B.1.1.7 are approximately equal distance from WA1 in opposite directions. The sera loosely cluster in the vicinity of the antigen they were raised against.

We repeated our analysis using an enzyme-linked immunosorbent assay (ELISA) with the respective spike proteins as substrates. While neutralization requires binding of antibodies to a limited number of epitopes mostly on RBD and NTD, many more binding epitopes exist on the spike protein [8] . Therefore, more even reactivity was expected. We did detect differences in reactivity when binding was tested against the respective matched spikes (Fig 3A; geometric mean area under the curve (AUC) values of 13,328, 10,317, 20,086, and 11,373 for wild type, B.1.1.7, B.1.351, and P.1, respectively), but while these differences were statistically significant in 3 cases, they were relatively small. However, it seemed that vaccination with B.1.351 induced slightly more homologous binding antibodies compared to the other immunogens. Low background reactivity was detected in sera of the control animals (Fig 3B) .

Both wild-type spike and B.1.1.7 spike induced relatively even binding antibody responses (Fig 3C and 3D shown. Statistical significance was tested with an ANOVA corrected for multiple comparisons. P values are shown for comparisons that resulted in statistical significance. Underlying raw data can be found in the S1 Data. LOD, limit of detection; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2.

https://doi.org/10.1371/journal.pbio.3001384.g001

These discrepancies between neutralization and binding antibody profiles allowed us to calculate ratios between binding and neutralizing antibodies. The best (higher) ratios (indicating a higher proportion of neutralizing antibodies) were found in sera from wild-type and B.1.1.7-vaccinated mice (S1 Fig). For each vaccination group, the ratio was always best against the homologous virus and dropped with antigenic distance (S1 Fig) . The most stable ratio was observed for P.1-vaccinated animals (S1 Fig).

Finally, we wanted to assess if the induced neutralizing antibody responses can protect animals from challenge with prototypic SARS-CoV-2 strain WA1. Since BALB/c mice are not susceptible to this virus, they had to be presensitized via intranasal transduction with adenovirus expressing human angiotensin converting enzyme 2 (hACE2) before challenge, as previously described. The main readout for the challenge experiment were virus titers in the lungs of infected animals. On day 2 postchallenge, control animals showed high viral loads in their lungs (approximately 10 6 plaque forming units per ml of lung homogenate) (Fig 4A) . In contrast, no virus was detected in wild-type and P.1 spike-vaccinated animals. For B.1.1.7 and B.1.351 spike-vaccinated animals, one animal per group showed traces of virus replication in the lung, but titers were barely above the limit of detection. On day 5 postinfection, no virus , sera as squares, in the color of the antigen they were raised against. The X and Y axes both correspond to antigenic distance, with one grid line corresponding to a 2-fold serum dilution in the neutralization assay. The antigens and sera are arranged on the map such that the distances between them best represent the distances measured in the neutralization assay. Underlying raw data can be found in the S1 Data.

https://doi.org/10.1371/journal.pbio.3001384.g002

was detectable in the lungs of vaccinated individuals, while control animals still showed high virus loads (Fig 4B) .

The emergence of SARS-CoV-2 variants is concerning both in terms of infection control (because many variants are more infectious), as well as in terms of vaccine effectiveness, due to the potential for immune escape. While several vaccines, which are either in clinical development or already in use, show good efficacy or effectiveness against most variants [19, 20, 24, 25] , 4. Vaccination with spike proteins of B.1.1.7, B.1.351, and P.1 protects against challenge with wild-type SARS-CoV-2 in a mouse model. (A, B) All groups of vaccinated mice were challenged with authentic SARS-CoV-2 after sensitization with AdV-hACE2 five days prior to infection. After infection, viral loads in the lungs were quantified via a plaque assay on day 2 (A) and day 5 (B). Underlying raw data can be found in the S1 Data. AdV-hACE2, adenovirus-human angiotensin converting enzyme 2; PFU, plaque-forming unit; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; wt, wild type.

https://doi.org/10.1371/journal.pbio.3001384.g004

the vaccine antigens may need to be updated at some point to cover variants that evade neutralizing antibodies more efficiently, like B.1.1.529 (Omicron). However, if variants cocirculate, it will be difficult to select the "right" variant that induces good immune responses across the board. Here, we have tested the cross-neutralization activity of wild type, B.1.1.7, B.1.351, and P.1 adjuvanted protein vaccines in the mouse model. We found that P.1 induces the most balanced immune response across the four tested antigens, supported by four sera raised against P.1 positioned centrally in the antigenic map between WA1, B.1.351, and P.1. Interestingly, while B.1.351 and P.1 share 2 of their RBD mutations and have a mutated residue at position 417 in common (although to different amino acids), a sharp drop in neutralizing activity from B.1.351 to P.1 was observed. However, this relationship was asymmetric, since the drop from P.1 to B.1.351 was much smaller. When considering the results from this study, P.1 should likely be the chosen immunogen for updated vaccines in our mouse model. Our mouse data are similar compared to human cross-neutralization data with the same four variants published by Liu and colleagues [26] . This suggests that mice may be a good model system to study antigenic variability among variants. Such model systems are of importance, as they ensure the continued availability of first-infection sera for the characterization of novel variants. However, there may be subtle differences between mouse strains and certainly between mice and humans, which need to be further explored. Interestingly, binding was much less affected than neutralization. There could be several reasons for that. One reason could be reduced antibody affinity that still allows binding but does not support neutralization anymore. Another reason could be that only a small number of epitopes are targeted by neutralizing antibodies while many more epitopes exist (especially outside the RBD and NTD) that are bound by nonneutralizing antibodies. If some of the neutralizing antibodies lose binding, the effect on overall binding is small because so many nonneutralizing antibodies still bind different epitopes on the very large spike. Similar findings have recently been reported in humans [27] . Importantly, all spike antigens, independently of the lineage, provided robust protection against challenge with the prototypic WA1 strains, suggesting that "updated" vaccines-especially if they induce high neutralizing antibody titers-would sufficiently protect against most other circulating variants as well as the prototypic SARS-CoV-2 strain. Of note, we do not think that the low virus titer (barely above the limit of detection) in one of the B.1.1.7 and in one of the B.1.351-vaccinated animals changes this conclusion. While challenge with variant viruses was not possible at this point in time in the selected mouse system (some variants bind to mouse ACE2 also, making comparisons complicated), we plan to evaluate cross-protection in more detail in the hamster model in the future. However, our work addresses the very pertinent question if a variant-based vaccine (as being developed by several vaccine producers) would protect against a mismatched/heterologous virus.

Our work here has focused on neutralizing and binding antibodies, which have been implicated as correlates of protection for SARS-CoV-2 vaccine-induced immunity [28, 29] , and reduction in neutralizing antibodies in sera from convalescent individuals and vaccinees against variants has been observed. However, T-cell responses very likely contribute to protection from COVID-19 as well. We have not analyzed T-cell responses in our experimental animals, but others have shown that the impact of variants on these responses is minimal [30] . Another caveat of our study is that we were not able to include B.1.617.2, B.1.617.1, C.37, and B.1.1.529 in our analysis even though these are currently important variants.

In summary, we found that neutralizing titers are always highest against the homologous virus but that antigenic relationships are not necessarily symmetric and that some variant spike proteins induced more balanced responses (e.g., P.1) than others (B. 1.351 and B.1.1.7) . In addition, the drop in binding antibody is much lower than the drop in neutralizing activity. Nonneutralizing binding antibodies have been shown to play an important role in protection for other diseases caused by virus infections including Ebola virus disease and influenza A and B viruses [31] [32] [33] [34] . The maintenance of binding antibody and T-cell responses against variants could partially explain the maintenance of vaccine effectiveness, despite the occasional steep drops in neutralizing antibody titers.

All recombinant proteins were expressed and purified using Expi293F cells (Life Technologies, Carlsbad, CA), as described in detail previously [22, 35] . The spike gene of each respective variant (EPI_ISL_703454, EPI_ISL_745160) was cloned into the pCAGGS vector and used to transfect cells. The cleavage site was deleted by removing the arginine residues, and prolines were added to position 986 and 987 to stabilize the spike trimer. The supernatant was clarified on day 4 posttransfection via centrifugation at 4,000g for 20 minutes. Ni 2+ -nitrilotriacetic acid (NTA) agarose (Qiagen, Hilden, Germany) was used to purify the protein, as described before [36, 37] . EPI_ISL_792680 was cloned into pcDNA3.4 for transient transfection. The endogenous leader peptide was replaced with the tPA secretion signal, 8XHIS and AviTag epitopes were appended, and the substitutions noted above introduced. The spike trimer was expressed by transient transfection in 293F cells and purified by affinity chromatography as previously described [38] .

The proteins used for ELISA were purchased from Sino Biological and include the following: 40589-V08B6, 40589-V08B7, 40589-V08B8, and 40589-V08B1.

Vero.E6 cells (ATCC CRL-1586, clone E6) were kept in culture using Dulbecco's modified Eagle medium (Gibco, Waltham, MA), which was supplemented with 10 mL of Antibiotic-Antimycotic (100 U/ml penicillin-100 μg/ml streptomycin-0.25 μg/ml amphotericin B; Gibco), 10% of fetal bovine serum (FBS; Corning, Corning, NY), and 1% HEPES (N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid; Gibco). Wild-type SARS-CoV-2 (isolate USA-WA1/2020), hCoV-19/South Africa/KRISP-K005325/2020 (B.1.351, BEI Resources NR-54009), hCoV-19/Japan/TY7-503/2021 (P.1, BEI resources NR-54982), and hCoV-19/ England/204820464/2020 (B.1.1.7, BEI Resources NR54000) were cultured in Vero.E6 cells for 3 days at 37˚C and then the supernatant was clarified via centrifugation at 1,000g for 10 minutes. Virus stocks were stored at −80˚C. The protocol was described in greater detail previously [22, 39] . All work with authentic SARS-CoV-2 was performed in a biosafety level 3 (BSL-3) facility following institutional guidelines.

All animal procedures were performed by adhering to the Institutional Animal Care and Use Committee (IACUC) guidelines of the Icahn School of Medicine at Mount Sinai IACUC and according to an approved protocol (IACUC-2014-0255). Research was conducted in concordance with the Animal Act PL99-158 (as amended). Six-to 8-week-old female, BALB/c mice were vaccinated via the intramuscular route with 3 μg of each respective protein with 1:1 mixture of AddaVax (Invivogen, San Diego, CA) in a total volume of 50 μL. After 3 weeks, mice were bled and vaccinated again. Three weeks later, mice were administered anesthesia via the intraperitoneal route and then intranasally transduced with AdV-hACE2 at 2.5 × 10 8 plaqueforming units (PFUs) per mouse. Anesthesia was prepared using 0.15 mg/kg of body weight ketamine and 0.03 mg/kg xylazine in water. Five days later, all mice were infected with wildtype SARS-CoV-2 intranasally with 1 × 10 5 PFU. Mice were humanely sacrificed on day 2 and day 5 for assessment of virus in the lungs. Lungs were homogenized using special tubes and a BeadBlaster 24 (Benchmark, Sayreville, NJ) homogenizer [40, 41] . Viral load in the lung was quantified via a classic plaque assay [42] .

Ninety-six-well plates (Immulon 4 HBX; Thermo Fisher Scientific, Waltham, MA) were coated with 2 μg/mL of each respective protein with 50 μL/well overnight at 4˚C. The next morning, the coating solution was discarded, and each plate was blocked with 100 μL/well of 3% nonfat milk (AmericanBio; catalog no. AB10109-01000) in phosphate buffered saline containing 0.01% Tween (PBS-T). Blocking solution was kept on the plates for 1 hour at room temperature (RT). Serum samples were tested starting at a dilution of 1:50 with 1:5-fold subsequent serial dilutions. Serum samples were added to the plates for 2 hours at RT. Next, the plates were vigorously washed 3 times with 200 μL/well of PBS-T. Anti-mouse IgG-horseradish peroxidase (HRP)-conjugated antibody (Rockland; catalog no. 610-4302) was used at a dilution of 1:3,000 in 1% nonfat milk in PBS-T, and 100 μL of this solution was added to each well for 1 hour at RT. The plates were washed 3 times with 200 μL/well of PBS-T and dried on paper towels. Developing solution was prepared in sterile water (WFI; Gibco) using SigmaFast OPD (ophenylenediamine dihydrochloride, catalog no. P9187; Sigma-Aldrich), and 100 μL was added to each well for a total of 10 minutes. To stop the reaction, 50 μL/well of 3 M hydrochloric acid was added, and the plates were read in a plate reader, Synergy 4 (BioTek, Winooski, VT), at an absorbance of 490 nanometers. Data were analyzed in GraphPad Prism 7.

Twenty-thousand Vero.E6 cells were seeded per well in a 96-well cell culture plate (Corning; 3340) 1 day prior to performing the assay. Serum samples were heat inactivated at 56˚C for 1 hour prior to use. Serum dilutions were prepared in 1× minimal essential medium (MEM; Gibco) supplemented with 1% FBS. Each virus was diluted to 10,000 50% tissue culture infectious doses (TCID 50 s)/mL, and 80 μL of virus and 80 μL of serum were incubated together for 1 hour at RT. After the incubation, 120 μL of virus-serum mixture was used to infect cells for 1 hour at 37˚C. Next, the virus-serum mix was removed and 100 μL of each corresponding dilution was added to each well. A volume of 100 μL of 1X MEM were also added to the plates to get to a total volume of 200 μL in each well. The cells were incubated at 37˚C for 3 days and then fixed with 10% paraformaldehyde (Polysciences, Warrington, PA) for 24 hours. The next day, cells were stained using a rabbit anti-nucleoprotein antibody (Invitrogen; PA5-81794) as primary antibody and a goat anti-rabbit secondary antibody conjugated to HRP (Invitrogen; 31460). This protocol was adapted from an earlier established protocol [22, 35, 43] .

A target distance from a serum to each virus is derived by calculating the difference between the logarithm (log 2 ) reciprocal neutralization titer for that particular virus and the log 2 reciprocal maximum titer achieved by that serum (against any virus). Thus, the higher the reciprocal titer, the shorter the target distance. As the log 2 of the reciprocal titer is used, a 2-fold change in titer will equate to a fixed change in target distance whatever the magnitude of the actual titers. Antigenic cartography [23] was then used to optimize the positions of the viruses and sera relative to each other on a map, minimizing the sum-squared error between map distance and target distance. Each virus is therefore positioned by multiple sera, and the sera themselves are also positioned only by their distances to the viruses. Hence, sera with different neutralization profiles to the virus panel are in separate locations on the map but contribute equally to positioning of the viruses. The antigenic cartography software used was written by Sam Wilks and is available as free and open-source software from https://www.antigenic-cartoraphy.org.

Supporting information S1 Fig. Neutralization over binding ratio varies for each group. (A) The neutralization over binding ratio was calculated and depicted for each group against the homologous virus and homologous spike protein. Statistical analysis was performed with an ANOVA corrected for multiple comparisons, and the p-values are indicated when statistical significance was present. Underlying raw data can be found in the S1 Data. (TIF) S1 Data. This file contains all raw data underlying the figures.

(XLSX)

Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity

Preliminary report of an outbreak of SARS-CoV-2 in mink and mink farmers associated with community spread

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Investigation of novel SARS-CoV-2 variant Variant of Concern 202012/01 Technical briefing 5

Detection of a SARS-CoV-2 variant of concern in South Africa

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell. 2021. Epub

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell. 2021. Epub

A neutralizing human antibody binds to the Nterminal domain of the Spike protein of SARS-CoV-2

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

Infection-and vaccineinduced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Antibody evasion by the P.1 strain of SARS-CoV-2

Vaccination NSGfC-. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Covid-19 Vaccine against the B.1.351 Variant

An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening

Mapping the antigenic and genetic evolution of influenza virus

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

Effectiveness of COVID-19 vaccines against the B.1.617.2 variant

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients

Evidence for antibody as a protective correlate for COVID-19 vaccines

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees

Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo

Antibody-mediated protection against Ebola virus

Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection

Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice

A serological assay to detect SARS-CoV-2 seroconversion in humans

Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system

Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice

Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell. 2021. Epub

Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection. bioRxiv. 2020. Epub

Monoclonal Antibodies with Neutralizing Activity and Fc-Effector Functions against the Machupo Virus Glycoprotein

Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model. mBio

Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate

We would like to thank Dr. Randy A. Albrecht for oversight of the conventional BSL3 biocontainment facility, which makes our work with live SARS-CoV-2 possible. We are also grateful for Mount Sinai's leadership during the COVID-19 pandemic. We want to especially thank Drs. Peter Palese, Carlos Cordon-Cardo, Dennis Charney, David Reich, and Kenneth Davis for their support. We thank Sam Wilks for the antigenic cartography toolkit, and Sam Wilks, Eric LeGresley, and Sina Tureli for deep background on SARS-CoV-2 antigenic variation.